clofibrate has been researched along with Reperfusion Injury in 5 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 7.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 5.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 3.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| "This study examined the effects of simvastatin (10 mg/ kg) and VULM 1457 (50 mg/kg), an ACAT inhibitor, in the heart model of 6 min ischemia followed by 10 min reperfusion injury in the diabetic-hypercholesterolaemic (DM-HCH) rats." | 3.73 | Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats. ( Adameová, A; Faberová, V; Kuzelová, M; Svec, P, 2006) |
| " To examine the role of stimulated FAO during ischemia, Etomoxir (Eto), clofibrate, and WY-14,643 compounds were given 5 days prior to the induction of ischemia/reperfusion (I/R) injury." | 3.70 | Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. ( Crew, MD; Dai, G; Gonzalez, FJ; Peters, JM; Portilla, D; Proia, AD, 2000) |
| "Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression." | 1.91 | PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response. ( Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez-Aguilar, M | 1 |
| Ibarra-Lara, L | 1 |
| Cano-Martínez, A | 1 |
| Soria-Castro, E | 1 |
| Castrejón-Téllez, V | 1 |
| Pavón, N | 1 |
| Osorio-Yáñez, C | 1 |
| Díaz-Díaz, E | 1 |
| Rubio-Ruíz, ME | 1 |
| Sivarajah, A | 1 |
| Chatterjee, PK | 1 |
| Hattori, Y | 1 |
| Brown, PA | 1 |
| Stewart, KN | 1 |
| Todorovic, Z | 1 |
| Mota-Filipe, H | 1 |
| Thiemermann, C | 1 |
| Adameová, A | 2 |
| Kuzelová, M | 2 |
| Faberová, V | 2 |
| Svec, P | 2 |
| Ravingerová, T | 1 |
| Portilla, D | 1 |
| Dai, G | 1 |
| Peters, JM | 1 |
| Gonzalez, FJ | 1 |
| Crew, MD | 1 |
| Proia, AD | 1 |
5 other studies available for clofibrate and Reperfusion Injury
| Article | Year |
|---|---|
PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response.
Topics: Animals; Arrhythmias, Cardiac; Atrial Natriuretic Factor; Clofibrate; Inflammation; Ischemia; Metabo | 2023 |
Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat.
Topics: Animals; Clofibrate; Gene Expression; Intercellular Adhesion Molecule-1; Kidney; Male; Pyrimidines; | 2002 |
Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Diabete | 2006 |
The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo.
Topics: Animals; Anti-Arrhythmia Agents; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; | 2007 |
Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure.
Topics: Acute Kidney Injury; Animals; Blood Urea Nitrogen; Carnitine O-Palmitoyltransferase; Clofibrate; Cre | 2000 |